Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Earnings Conference Call dated February 01, 2024 with Investors/ Analysts for Q3 & 9M FY24 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result
Dr. Lal Pathlabs Results Earnings Call for Q3FY24
Conference Call with Dr. Lal Pathlabs Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript. Q3FY24 Quarterly & 9MFY24 Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare Services company Dr. Lal Pathlabs announced Q3FY24 & 9MFY24 results: Q3FY24: Revenue: In Q3FY24, Dr Lal PathLabs reported a revenue of Rs 539 crore, marking a 10.1% increase from the Rs 489 crore recorded in Q3FY23. Operating Expenditure: The operating expenditure rose by 5.8% to Rs 398 crore in the current quarter from Rs 376 crore in the corresponding quarter of the previous fiscal year. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): The Company's EBITDA escalated significantly by 24.6%, amounting to Rs 141 crore as compared to Rs 113 crore in Q3FY23, resulting in an EBITDA margin of 26.1%. Profit After Tax (PAT): PAT witnessed a substantial increase of 53.3% to Rs 82 crore in Q3FY24 from Rs 54 crore in Q3FY23, achieving a PAT margin of 15.3%. Earnings per Share (EPS): EPS climbed up to Rs 9.8, reflecting a remarkable 53.2% gain over the Rs 6.4 reported in Q3FY23. 9MFY24: Revenue: the Company's cumulative revenue reached Rs 1681 crore, which is a 10.2% increment year-on-year. Operating Expenditure: operating expenditure increased by 5.6% to Rs 1217 crore. EBITDA: EBITDA grew by 24.1% to Rs 465 crore, from Rs 374 crore with an improved margin of 27.6%. Profit After Tax (PAT): The nine months ended December 31, 2023, saw PAT soar by 50.5% to Rs 277 crore. Earnings per Share (EPS): EPS stood at Rs 32.9, an increase of 49.5% from the previous year. Result PDF Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q3 & 9M FY 24 Financial Results Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on un-audited Financial Results for the Quarter and Nine Months ended December 31, 2023 Dr. Lal PathLabs Ltd - 539524 - Board Of Directors In Their Meeting Held On February 01, 2024 Approved Payment Of 2Nd Interim Dividend For FY 2023-24
Board of Directors in their meeting held on February 01, 2024 approved payment of 2nd Interim Dividend for FY 2023-24 Dr. Lal PathLabs Ltd - 539524 - Corporate Action-Board approves Dividend
Board of Directors in their meeting held on February 01, 2024 approved payment of 2nd Interim Dividend for FY 2023-24 Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Dividend Updates
Board of Directors in their meeting held on February 01, 2024 inter-alia approved payment of 2nd Interim Dividend for FY 2023-24 Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting Dated February 01, 2024
Outcome of Board Meeting held on February 01, 2024 Dr. Lal PathLabs Ltd - 539524 - Financial Results For The Quarter And Nine Months Ended December 31, 2023
Financial Results for the quarter and nine months ended December 31, 2023